Population attributes affecting the prevalence of BRCA mutation carriers in epithelial ovarian cancer cases in Israel

被引:58
作者
Hirsh-Yechezkel, G [1 ]
Chetrit, A
Lubin, F
Friedman, E
Peretz, T
Gershoni, R
Rizel, S
Struewing, JP
Modan, B
机构
[1] Chaim Sheba Med Ctr, Gertner Inst Epidemiol & Hlth Policy Res, Canc Epidemiol Unit, IL-52621 Tel Hashomer, Israel
[2] Chaim Sheba Med Ctr, Oncogenet Unit, Tel Hashomer, Israel
[3] Hadassah Univ Hosp, Oncol Unit, IL-91120 Jerusalem, Israel
[4] Rambam Med Ctr, Genet Unit, Haifa, Israel
[5] Rabin Med Ctr, Oncol Unit, Petah Tiqwa, Israel
[6] Natl Canc Inst, Lab Populat Genet, Bethesda, MD USA
[7] Tel Aviv Univ, Sackler Sch Med, Stanley Steyer Inst Canc Res, IL-69978 Tel Aviv, Israel
关键词
ovarian cancer; BRCA carriers; Israeli population;
D O I
10.1016/S0090-8258(03)00152-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective. The objective was to evaluate the prevalence of BRCA1/2 mutations in selected categories of ovarian cancer patients in Israel. Methods. Blood samples and specimens of ovarian tumors were obtained in the course of a national case control study of women with ovarian cancer in Israel. Eight hundred ninety-six patients with epithelial ovarian cancer, 40 cases with nonepithelial ovarian cancer, and 68 with primary peritoneal cancer were tested for the BRCA mutations. Analysis of the three common BRCA mutations in Israel (185delAG, 5382insC in BRCA1, and 6174delT in BRCA2) was done using a multiplex polymerase chain reaction assay. A multivariate logistic regression model was used to assess the association of mutation carrier status and other factors (age, origin, family history, and clinical variables). Results. Of the 779 invasive epithelial ovarian cancer cases, 29.4% were mutation carriers. The prevalence of the mutations was higher among women below age 60 and in more advanced cases. The prevalence was low in mucinous tumors. There was almost a twofold excess of mutations among women with positive family history (45.7%), but still 26.5% of the family history negative cases were carriers. As expected, we found a higher rate of mutation carriers among the Ashkenazi group (34.2%) and 55% among Ashkenazi women with positive family history. No subjects born in North Africa were mutation positive. Conclusion. BRCA mutations are strongly associated with ovarian cancer and they are present in variable rates in distinct age, ethnic, and histopathologic categories. (C) 2003 Elsevier Science (USA). All rights reserved.
引用
收藏
页码:494 / 498
页数:5
相关论文
共 17 条
[1]  
Abeliovich D, 1997, AM J HUM GENET, V60, P505
[2]   High frequency of BRCA1 and BRCA2 germline mutations in Ashkenazi Jewish ovarian cancer patients, regardless of family history [J].
Beller, U ;
Halle, D ;
Catane, R ;
Kaufman, B ;
Hornreich, G ;
LevyLahad, E .
GYNECOLOGIC ONCOLOGY, 1997, 67 (02) :123-126
[3]  
KRAINER M, 1997, NEW ENGL J MED, V336, P1448
[4]  
LevyLahad E, 1997, AM J HUM GENET, V60, P1059
[5]   A population-based study of BRCA1 and BRCA2 mutations in Jewish women with epithelial ovarian cancer [J].
Lu, KH ;
Cramer, DW ;
Muto, MG ;
Li, EY ;
Niloff, J ;
Mok, SC .
OBSTETRICS AND GYNECOLOGY, 1999, 93 (01) :34-37
[6]   High frequency of BRCA1 185delAG mutation in ovarian cancer in Israel [J].
Modan, B ;
Gak, E ;
SadeBruchim, RB ;
HirshYechezkel, G ;
Theodor, L ;
Lubin, F ;
BenBaruch, G ;
Beller, U ;
Fishman, A ;
Dgani, R ;
Menczer, J ;
Papa, M ;
Friedman, E .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 276 (22) :1823-1825
[7]   Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation [J].
Modan, B ;
Hartge, P ;
Hirsh-Yechezkel, G ;
Chetrit, A ;
Lubin, F ;
Beller, U ;
Ben-Baruch, G ;
Fishman, A ;
Menczer, J ;
Struewing, JP ;
Tucker, MA ;
Wacholder, S ;
Ebbers, SM ;
Friedman, E ;
Piura, B .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (04) :235-240
[8]   BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer [J].
Moslehi, R ;
Chu, W ;
Karlan, B ;
Fishman, D ;
Risch, H ;
Fields, A ;
Smotkin, D ;
Ben-David, Y ;
Rosenblatt, J ;
Russo, D ;
Schwartz, P ;
Tung, N ;
Warner, E ;
Rosen, B ;
Friedman, J ;
Brunet, JS ;
Narod, SA .
AMERICAN JOURNAL OF HUMAN GENETICS, 2000, 66 (04) :1259-1272
[9]  
Muto MG, 1996, CANCER RES, V56, P1250
[10]   BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and ovarian cancer [J].
Schubert, EL ;
Mefford, HC ;
Dann, JL ;
Argonza, RH ;
Hull, J ;
King, MC .
GENETIC TESTING, 1997, 1 (01) :41-46